This study developed innovative cancer therapy—electroactive membrane-integrated liposome nanoparticles (Au@MIL NPs). Combining electroactive liposomes and gold nanoparticles, Au@MIL NPs efficiently disrupt cancer cells＇ redox balance, inducing apoptosis without harming normal cells. Mouse and canine studies confirmed efficacy and safety, highlighting its potential as a precise, low-side-effect cancer treatment.

Innovative Au@MIL NPs integrate Shewanella electroactive membranes with gold nanoparticles for intracellular electron interception, breaking away from conventional approaches to cancer drug design. This system actively disrupts cancer cell redox balance, increasing oxidative stress to induce apoptosis with high selectivity. Murine/canine models validated excellent efficacy, biocompatibility, and strong clinical translation potential, creating a new cancer treatment paradigm.

The innovative Au@MIL nanoparticles represent a novel cancer therapy that differs from traditional drug design approaches. With their unique mechanism, they hold strong potential for industrial application. These nanoparticles could become a new generation of cancer therapeutics, either replacing or complementing conventional treatments, while also advancing precision medicine and veterinary cancer care. Their high selectivity and low side-effect profile are particularly noteworthy.